Genfleet Therapeutics (Shanghai) Inc. clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 1 with a minor change only.

1. Notable

   GFH276 Combined With Cetuximab or Chemotherapy · Solid Tumors and…GFH276 Combined With Cetuximab or Chemotherapy · Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

   Recruitment opened

   Genfleet Therapeutics (Shanghai) Inc.·Phase 1/2· NCT07678593· Registry history of NCT07678593 on ClinicalTrials.gov (opens the registry)

   Updated Oct 5, 2026

2. Notable

   GFH375 Combined With GFS202A or GFH276 Versus GFH375…GFH375 Combined With GFS202A or GFH276 Versus GFH375 · Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation

   Recruitment opened

   Genfleet Therapeutics (Shanghai) Inc.·Phase 2· NCT07784374· Registry history of NCT07784374 on ClinicalTrials.gov (opens the registry)

   Updated Oct 2, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.